Hua Medicine Launches MYHOMSIS® for Diabetes, Pioneering Treatment in Hong Kong
- Hua Medicine’s dorzagliatin, branded as MYHOMSIS®, is the first innovative diabetes drug approved in Hong Kong.
- The launch positions Hong Kong as a hub for Hua Medicine's expansion into Southeast Asia and beyond.
- The company aims to establish a marketing network to enhance patient access to MYHOMSIS® across the region.
Hua Medicine Launches Groundbreaking Diabetes Treatment in Hong Kong
Hua Medicine, a prominent player in the pharmaceutical landscape, celebrates a milestone with the approval of its first-in-class glucokinase activator, dorzagliatin, branded as MYHOMSIS® (華領片®), for treating Type 2 diabetes in adults. The approval, granted by the Pharmaceutical Service of Hong Kong's Department of Health, marks a significant breakthrough as it becomes the first innovative drug for chronic metabolic diseases to gain clearance under the territory's "1+" regulatory framework. This regulatory mechanism enhances the efficiency of drug approvals, reflecting a forward-thinking approach to advancing healthcare solutions within Hong Kong. The New Drug Application for dorzagliatin received acceptance in September 2025, leading to this momentous step for the company.
MYHOMSIS®’s approval not only represents a critical achievement for Hua Medicine, but it also positions Hong Kong as a strategic hub for the company’s expansion into Southeast Asia and beyond. According to Cao Beili, Vice President of Hua Medicine, this launch underscores the company’s commitment to addressing the growing prevalence of diabetes, a significant health concern affecting millions globally. This strategic move dovetails with the broader goals of enhancing regional healthcare systems and fostering innovation within the field of diabetes treatment. Dr. Chen Li, the CEO and Founder, notes that the success of MYHOMSIS® highlights the international competitiveness of Chinese pharmaceutical innovations, underscoring the potential for Hua Medicine’s products to gain traction in global markets.
In addition to its Hong Kong launch, Hua Medicine actively pursues regulatory approval for dorzagliatin in the Macao Special Administrative Region. This endeavor is part of a larger strategy aimed at penetrating the Guangdong-Hong Kong-Macao Greater Bay Area, a region well-regarded for its medical resources and talent pool. The company envisions the establishment of a comprehensive marketing network and collaborative research initiatives across Southeast Asia, which will play a crucial role in further advancing clinical applications of dorzagliatin and enhancing patient access to this innovative treatment.
Beyond its Hong Kong development, Hua Medicine aims to leverage its regional advantages to expand its reach and availability of MYHOMSIS®. By focusing on securing its position within the local and regional markets, the company demonstrates a keen understanding of the dynamic healthcare landscape and its role in combating major chronic diseases like diabetes internationally. This strategic positioning is expected to bolster Hua Medicine’s growth trajectory and contribute significantly to public health outcomes in the regions it serves.